AtaiBeckley Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-08$4.45 RISE2026-03-27$3.35 PEAK2026-04-20$4.90 133d | -24.7% 109d | Missed | Missed | — | — | +46.3% 24d | Missed |
DROP2025-10-17$6.45 RISE2025-11-20$3.66 PEAK2025-12-08$4.45 52d | -43.3% 34d | Missed | Missed | — | — | +21.6% 18d | Missed |
DROP2025-02-12$2.55 RISE2025-06-23$2.02 PEAK2025-09-09$4.89 209d | -20.8% 131d | Missed | Missed | — | — | +142.1% 78d | Missed |
DROP2025-02-12$2.55 RISE2025-04-10$1.21 PEAK2025-07-03$2.77 141d | -52.5% 57d | Missed | Missed | — | — | +128.9% 84d | Missed |
DROP2025-02-12$2.55 RISE2025-04-08$1.21 PEAK2025-07-03$2.77 141d | -52.5% 55d | Missed | Missed | — | — | +128.9% 86d | Missed |
DROP2024-11-29$1.78 RISE2024-12-18$1.18 PEAK2025-02-12$2.55 75d | -33.7% 19d | Missed | Missed | — | — | +116.1% 56d | Missed |
DROP2024-07-16$1.64 RISE2024-10-31$1.06 PEAK2024-11-29$1.78 136d | -35.4% 107d | Missed | Missed | — | — | +67.9% 29d | Missed |
DROP2024-05-30$1.68 RISE2024-10-03$1.06 PEAK2024-11-29$1.78 183d | -36.9% 126d | Missed | Missed | — | — | +67.9% 57d | Missed |
DROP2024-04-08$2.60 RISE2024-08-14$1.17 PEAK2024-11-07$1.35 213d | -55.0% 128d | Missed | Missed | — | — | +15.4% 85d | Missed |
DROP2024-04-08$2.60 RISE2024-07-08$1.27 PEAK2024-07-16$1.64 99d | -51.2% 91d | Missed | Missed | — | — | +29.1% 8d | Missed |
DROP2024-04-08$2.60 RISE2024-07-05$1.27 PEAK2024-07-16$1.64 99d | -51.2% 88d | Missed | Missed | — | — | +29.1% 11d | Missed |
DROP2024-04-08$2.60 RISE2024-06-18$1.27 PEAK2024-07-16$1.64 99d | -51.2% 71d | Missed | Missed | — | — | +29.1% 28d | Missed |
DROP2024-03-07$2.19 RISE2024-03-22$1.63 PEAK2024-04-08$2.60 32d | -25.6% 15d | Missed | Missed | — | — | +59.5% 17d | Missed |
DROP2024-01-09$2.19 RISE2024-02-07$1.70 PEAK2024-04-08$2.60 90d | -22.4% 29d | Missed | Missed | — | — | +52.9% 61d | Missed |
DROP2023-07-31$2.09 RISE2023-11-30$1.04 PEAK2024-01-09$2.19 162d | -50.2% 122d | Missed | Missed | — | — | +110.6% 40d | Missed |
1–15 / 26 1 / 2 | |||||||
Compass Pathways advances COMP360 psilocybin for TRD, with Phase 3 success and a rolling NDA by 4Q26. Learn more about CMPS stock here.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the launch of a new Patient Impact Grant Program aimed at supporting non-profit organizations working to improve mental health outcomes through community initiatives, education and research. The clinical-stage biotechnology company said...
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 12, 2026, AtaiBeckley Inc. (NASDAQ:ATAI) reported Q1 EPS of (8c), versus the consensus estimate of (11c). Revenue totaled $954,000, versus the consensus estimate of $90,910. Co-Founder and CEO Srinivas Rao said the company’s $209.9M cash position is […]
U.S. President Donald Trump'sexecutive order to accelerate psychedelic drug development hasraised hopes among companies developing the drugs that it couldhelp attract more capital, but researchers...
Event context and recent move in AtaiBeckley AtaiBeckley (ATAI) has been drawing attention after recent trading, with the stock last closing at US$4.02 and showing mixed short term performance, including a slight decline over the past day and week, but gains over the past month. See our latest analysis for AtaiBeckley. While the 1 day and 7 day share price returns have slipped, the 90 day share price return of 12.46% and 1 year total shareholder return of 143.33% suggest momentum has been...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is moving toward a series of late-stage clinical inflection points in its psychedelic drug pipeline, with multiple Phase III and Phase II readouts expected over the next several years that could help define the outlook for its $1B portfolio, according to...
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) is preparing to launch its pivotal Phase 3 program for its lead treatment-resistant depression therapy in the second quarter of 2026, while projecting its cash reserves will support operations into 2029 as the company advances multiple mental health...
AtaiBeckley (NASDAQ:ATAI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 46.67 percent increase over losses of $(0.15) per share from the
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026Consistent, convergent improvements...
AtaiBeckley Inc. (NASDAQ:ATAI) is one of the best fast growing penny stocks to buy right now. On April 22, AtaiBeckley announced expanded Phase 2a results for EMP-01 (oral R-MDMA), showing significant and consistent improvements for adults with Social Anxiety Disorder/SAD. The trial showed a 38% reduction in patient-reported symptoms and a 32% reduction in real-world […]
Health officials explored restricting specific antidepressants among SSRI drugs-sources
In April 2026, AtaiBeckley Inc. reported expanded Phase 2a data showing its oral R-MDMA candidate EMP-01 produced clinically meaningful, well-tolerated improvements in multiple symptom, functioning, and behavioral measures for adults with Social Anxiety Disorder, without severe or serious adverse events. Alongside symptom scale gains, nearly half of EMP-01 patients were rated as responders by both clinicians and patients by Day 43, suggesting perceived real-world benefits in everyday social...
Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health’s 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participant Advocacy Network (PsyPAN) to strengthen participant involvement in psychedelic clinical...
Recent White House and FDA actions fast-track psychedelic depression drug approvals. Click here for more information on Market Outlook.
NEW YORK, April 27, 2026 -- AtaiBeckley Inc. , a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health...
Compass Pathways, the developer of synthetic psilocybin, announced it had received a government voucher.
https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order.html
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ATAI | +9.42% | +23.10% | +10.76% | +96.10% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +6.45% | +28.81% | +14.20% | +83.42% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 1.98M | $6.99M | 0.01% | New | 2026-03-31 |
| StateStreet | passive | 1.14M | $4.05M | 0.00% | New | 2026-03-31 |
| Citadel | multi-strat | 664.7K | $2.35M | 0.00% | New | 2026-03-31 |
| DEShaw | quant | 27.4K | $97.06K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.11 | — | — |
| 2026-03-06 | -0.11 | -1.73 | -1441.61% |
| 2025-11-12 | -0.12 | -0.28 | -125.28% |
| 2025-08-14 | -0.12 | -0.14 | -18.31% |
| 2025-05-14 | -0.18 | -0.15 | +16.67% |
| 2025-03-17 | -0.15 | -0.24 | -60.00% |
| 2024-11-13 | -0.16 | -0.16 | — |
| 2024-08-13 | -0.16 | -0.36 | -129.78% |
| 2024-05-15 | -0.18 | -0.17 | +5.56% |
| 2024-03-28 | -0.16 | -0.12 | +26.15% |
| 2023-11-14 | -0.20 | 0.25 | +226.58% |
| 2023-08-10 | -0.21 | -0.21 | -1.61% |
| 2023-05-11 | -0.22 | -0.21 | +3.42% |
| 2023-03-24 | -0.23 | -0.28 | -23.27% |
| 2022-11-10 | -0.24 | -0.22 | +8.11% |
| 2022-08-15 | -0.24 | -0.24 | +0.06% |